Otis W. Brawley - 16 Jun 2021 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Heather D. Turner, as Attorney-in-fact
Issuer symbol
LYEL
Transactions as of
16 Jun 2021
Net transactions value
$0
Form type
3
Filing time
16 Jun 2021, 19:14:39 UTC
Next filing
17 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LYEL Option (right to buy) 16 Jun 2021 Common Stock 400,000 $12.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in equal monthly installments over the thirty-six months following April 9, 2021. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.